Edward Keystone

37.3k total citations · 13 hit papers
404 papers, 24.5k citations indexed

About

Edward Keystone is a scholar working on Rheumatology, Hematology and Genetics. According to data from OpenAlex, Edward Keystone has authored 404 papers receiving a total of 24.5k indexed citations (citations by other indexed papers that have themselves been cited), including 309 papers in Rheumatology, 139 papers in Hematology and 106 papers in Genetics. Recurrent topics in Edward Keystone's work include Rheumatoid Arthritis Research and Therapies (293 papers), Autoimmune and Inflammatory Disorders Research (127 papers) and Systemic Lupus Erythematosus Research (103 papers). Edward Keystone is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (293 papers), Autoimmune and Inflammatory Disorders Research (127 papers) and Systemic Lupus Erythematosus Research (103 papers). Edward Keystone collaborates with scholars based in Canada, United States and United Kingdom. Edward Keystone's co-authors include Paul Emery, Mark C. Genovese, Larry W. Moreland, Michael Schiff, Michael E. Weinblatt, Steven Fischkoff, Roy Fleischmann, Elliot Chartash, Joan M. Bathon and Désirée van der Heijde and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Investigation and Nature Medicine.

In The Last Decade

Edward Keystone

390 papers receiving 23.5k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial

2003 1.4k citations Edward Keystone et al. Arthritis & Rheumatism profile →
A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis

2000 1.4k citations Edward Keystone, Mark C. Genovese et al. profile →
Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeks

2006 1.3k citations Mark C. Genovese, Edward Keystone et al. Arthritis & Rheumatism profile →
Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo‐controlled, 52‐week trial

2004 956 citations Edward Keystone et al. Arthritis & Rheumatism profile →
Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial

2004 940 citations Josef S Smolen, Edward Keystone et al. Arthritis & Rheumatism profile →
IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

2008 866 citations Edward Keystone et al. Annals of the Rheumatic Diseases profile →
Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis

2017 621 citations Edward Keystone, Yoshiya Tanaka et al. profile →
Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two‐year radiographic and clinical outcomes

2002 573 citations Mark C. Genovese, Edward Keystone et al. Arthritis & Rheumatism profile →
Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management

2003 559 citations Edward Keystone et al. profile →
Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)

2005 502 citations Arthur Kavanaugh, Gerd R Burmester et al. Arthritis & Rheumatism profile →
Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: Findings of a fifty‐two–week, phase III, multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group study

2008 465 citations Edward Keystone et al. Arthritis & Rheumatism profile →
Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve‐month data from a twenty‐four–month phase III randomized radiographic study

2013 456 citations Yoshiya Tanaka, Edward Keystone et al. Arthritis & Rheumatism profile →
Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study

2008 432 citations Edward Keystone, Mark C. Genovese et al. Annals of the Rheumatic Diseases profile →

Peers

Countries citing papers authored by Edward Keystone

Since Specialization

Citations

This map shows the geographic impact of Edward Keystone's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edward Keystone with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edward Keystone more than expected).

Fields of papers citing papers by Edward Keystone

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Edward Keystone. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edward Keystone. The network helps show where Edward Keystone may publish in the future.

Co-authorship network of co-authors of Edward Keystone

This figure shows the co-authorship network connecting the top 25 collaborators of Edward Keystone. A scholar is included among the top collaborators of Edward Keystone based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Edward Keystone. Edward Keystone is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Having More Tender Than Swollen Joints is Associated With Worse Function and Work Impairment in Patients With Early Rheumatoid Arthritis 2024 ·ACR Open Rheumatology ·Charis F. Meng, Yvonne Lee, Orit Schieir, Marie‐France Valois, (unknown), Gilles Boire, Glen Hazlewood, Carol Hitchon, Edward Keystone, D. Tin, Carter Thorne, Louis Bessette, Janet Pope, Susan J. Bartlett, Vivian P. Bykerk	2
2	Efficacy and safety of CT-P47 versus reference tocilizumab: 32-week results of a randomised, active-controlled, double-blind, phase III study in patients with rheumatoid arthritis, including 8 weeks of switching data from reference tocilizumab to CT-P47 2024 ·RMD Open ·Josef S Smolen, (unknown), Artur Racewicz, Janusz Jaworski, Agnieszka Zielińska, Marek Krogulec, Sławomir Jeka, Rafał Wojciechowski, (unknown), Anna Dudek, Magdalena Krajewska–Włodarczyk, Paweł Hrycaj, Piotr Adrian Klimiuk, Gerd R Burmester, (unknown), Yunju Bae, (unknown), (unknown), (unknown), Edward Keystone	3
3	Pharmacokinetics and Safety of Intravenous Candidate Biosimilar CT‐P47 and Reference Tocilizumab: A Randomized, Double‐Blind, Phase 1 Study 2024 ·The Journal of Clinical Pharmacology ·Miwa Haranaka, Takashi Eto, Takanori Tanaka, (unknown), Gerd R Burmester, Edward Keystone, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Josef S Smolen	2
4	POS0614 ASSOCIATIONS BETWEEN DISEASE ACTIVITY, PHYSICAL FUNCTION AND ANTI-RHEUMATIC MEDICATIONS WITH ALL-CAUSE MORTALITY IN RHEUMATOID ARTHRITIS (RA): DATA FROM A CANADIAN RA REGISTRY 2024 ·Annals of the Rheumatic Diseases ·(unknown), (unknown), (unknown), Bindee Kuriya, (unknown), Edward Keystone, Janet Pope, Claire Bombardier	1
5	Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 administered by auto-injector or pre-filled syringe: a randomized, open‑label, single-dose phase I study 2024 ·Expert Opinion on Biological Therapy ·Kyung‐Sang Yu, (unknown), Dongseong Shin, Min Kyu Park, (unknown), (unknown), Min‐Gul Kim, Edward Keystone, Josef S Smolen, Sunghyun Kim, Yunju Bae, (unknown), (unknown), (unknown), (unknown), Jae‐Yong Lee, Gerd R Burmester	2
6	Discontinuation of tofacitinib and TNF inhibitors in patients with rheumatoid arthritis: analysis of pooled data from two registries in Canada 2023 ·BMJ Open ·Mohammad Movahedi, D. Choquette, Louis Coupal, (unknown), Xiuying Li, Edward Keystone, Claire Bombardier, (unknown)	4
7	A Bridge Too Far? Real‐World Practice Patterns of Early Glucocorticoid Use in the Canadian Early Arthritis Cohort 2021 ·ACR Open Rheumatology ·Kathleen M. Andersen, Orit Schieir, Marie‐France Valois, Susan J. Bartlett, Louis Bessette, Gilles Boire, Boulos Haraoui, Glen Hazlewood, Carol Hitchon, Edward Keystone, Janet Pope, D. Tin, (unknown), Vivian P. Bykerk, (unknown)	10
8	Joint Estimation of Remission and Response for Methotrexate‐Based DMARD Options in Rheumatoid Arthritis: A Bivariate Network Meta‐Analysis 2019 ·ACR Open Rheumatology ·(unknown), Rob Deardon, Cheryl Barnabé, Vivian P. Bykerk, Susan J. Bartlett, Louis Bessette, Gilles Boire, Carol Hitchon, Edward Keystone, Janet Pope, Orit Schieir, D. Tin, Carter Thorne, Glen Hazlewood, (unknown)	4
9	Treatment Strategies in Early Rheumatoid Arthritis Methotrexate Management: Results From a Prospective Cohort 2019 ·Arthritis Care & Research ·Cristiano Soares de Moura, Orit Schieir, Marie‐France Valois, Carter Thorne, Susan J. Bartlett, Janet Pope, Carol Hitchon, Gilles Boire, Boulos Haraoui, Glen Hazlewood, Edward Keystone, D. Tin, Vivian P. Bykerk, Sasha Bernatsky, (unknown)	12
10	High Adherence to System‐Level Performance Measures for Rheumatoid Arthritis in a National Early Arthritis Cohort Over Eight Years 2018 ·Arthritis Care & Research ·Claire Barber, Orit Schieir, Diane Lacaille, Deborah A. Marshall, Cheryl Barnabé, Glen Hazlewood, Carter Thorne, Vandana Ahluwalia, Susan J. Bartlett, Gilles Boire, Boulos Haraoui, Carol Hitchon, Edward Keystone, D. Tin, Janet Pope, (unknown), Vivian P. Bykerk, (unknown)	13
11	The effect of rheumatoid arthritis–associated autoantibodies on the incidence of cardiovascular events in a large inception cohort of early inflammatory arthritis 2016 ·Lara D. Veeken ·(unknown), Janet Pope, Carol Hitchon, Gilles Boire, Orit Schieir, Daming Lin, Carter Thorne, D. Tin, Edward Keystone, Boulos Haraoui, Shahin Jamal, Vivian P. Bykerk	23
12	Reliability and Validity Of Patient-Reported Joint Counts and Determinants Of Disagreement With The Physician In Recent Onset Rheumatoid Arthritis 2013 ·Data Archiving and Networked Services (DANS) ·K. Visser, Janet Pope, (unknown), (unknown), Susan J. Bartlett, Gilles Boire, Carol Hitchon, Carter Thorne, B. Haraoui, D. Tin, Edward Keystone, (unknown)	1
13	The effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis 2013 ·Lara D. Veeken ·Daniel E. Fürst, Jonathan Kay, Mary Chester Wasko, Edward Keystone, Arthur Kavanaugh, Atul Deodhar, Frederick T. Murphy, Jeanette H. Magnus, Elizabeth C. Hsia, Benjamin Hsu, Stephen Xu, Mahboob U. Rahman, Mittie K. Doyle	26
14	Safety profile of subcutaneous abatacept focusing On clinically relevant events in patients with rheumatoid arthritis and up to 4.5 years of exposure 2012 ·Queensland's institutional digital repository (The University of Queensland) ·Rieke Alten, Jeffrey Kaine, Edward Keystone, Peter Nash, I. Delaet, (unknown), Mark C. Genovese	3
15	Tofacitinib, an Oral Janus Kinase Inhibitor, in Combination with Methotrexate Reduced the Progression of Structural Damage in Patients with Rheumatoid Arthritis: Year 2 Efficacy and Safety Results From a 24-Month Phase 3 Study 2012 ·Arthritis & Rheumatism ·D. van der Heijde, Yoshiya Tanaka, R Fleischmann, Edward Keystone, J.M. Kremer, Cristiano A. F. Zerbini, Mario H. Cardiel, S. Cohen, Peter Nash, Yu Song, Dana Tegzová, Bradley T. Wyman, David Gruben, Birgitta Benda, Gene V. Wallenstein, S. Krishnaswami, Samuel H. Zwillich, John Bradley, Carol A. Connell, (unknown)	4
16	Identification of the NF-κB activating protein-like locus as a risk locus for rheumatoid arthritis 2012 ·Annals of the Rheumatic Diseases ·Gang Xie, Yue Lu, Ye Sun, (unknown), Edward Keystone, Peter K. Gregersen, Robert M. Plenge, Christopher I. Amos, Katherine A. Siminovitch	8
17	DISCONNECT BETWEEN DISEASE ACTIVITY AND JOINT SPACE NARROWING FOR PATIENTS WITH EARLY RA TREATED WITH ADALIMUMAB PLUS METHOTREXATE BUT NOT METHOTREXATE ALONE: CASE FOR ANTI-TNF CARTILAGE PROTECTION 2011 ·Lara D. Veeken ·R. Landewé, Edward Keystone, Smolen Js, Mary B. Goldring, B. Guérette, Kartick Patra, M. Cifaldi, (unknown)	2
18	Mutant p53 in bone marrow stromal cells increases VEGF expression and supports leukemia cell growth 2003 ·Experimental Hematology ·Aru Narendran, Hooman Ganjavi, (unknown), Alison Connor, (unknown), Edward Keystone, David Malkin, Melvin H. Freedman	47
19	Genetic bias in immune responses to a cassette shared by different microorganisms in patients with rheumatoid arthritis. 1997 ·Journal of Clinical Investigation ·Antonio La Cava, J. Lee Nelson, William Ollier, Alex J. MacGregor, Edward Keystone, Carter Thorne, John F. Scavulli, Charles C. Berry, Dennis A. Carson, Salvatore Albani	58
20	Proceedings of the 42nd annual meeting of the american rheumatism association a section of the arthritis foundation june 1 & 2, 1978 new york city abstracts of papers presented 1978 ·Arthritis & Rheumatism ·Thomas Abel, Murray B. Urowitz, H A Smythe, Edward Keystone, (unknown), Christine K. Abrass, Kenneth M. Nies, Sarah James, (unknown), Richard J. Glassock, Frank C. Arnett, Mark S. Hochberg, Wilma Β. Bias, Carlos Arroyave, Eng M. Tan, (unknown), (unknown)	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact